Prostate Cancer Therapeutics Market Report 2026

The prostate cancer therapeutics market size has grown strongly in recent years. It will grow from $12.88 billion in 2025 to $13.96 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising prostate cancer incidence, aging male population, advancements in oncology drugs, hospital-based cancer care, increased cancer screening.

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to precision oncology adoption, biomarker-driven therapies, growth in oral oncology drugs, expanding immunotherapy pipeline, rising healthcare expenditure. Major trends in the forecast period include growing adoption of targeted therapies, rising use of parp inhibitors, expansion of immunotherapy in oncology, shift toward oral cancer drugs, precision medicine-based treatment selection.

The rising incidence of prostate cancer is expected to drive the growth of the prostate cancer therapeutics market in the coming years. Prostate cancer is a disease in which malignant cells develop in the tissues of the prostate gland, most commonly affecting older men. Its increasing incidence is largely due to the aging population, as the risk of developing the disease rises with age and longer life expectancy allows more men to live long enough to be affected. Prostate cancer therapeutics manage the disease by targeting cancer cells, slowing progression, and improving quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For example, in January 2025, Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, reported that the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Consequently, the increasing incidence of prostate cancer is fueling the growth of the prostate cancer therapeutics market.

Major companies operating in the prostate cancer therapeutics market are focusing on developing innovative treatments, such as oral once-a-day pills for advanced prostate cancer, to improve patient compliance and overall treatment outcomes. These oral pills are taken daily to manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India’s first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the need for injections administered by healthcare providers, providing greater patient convenience. This launch represents a major advancement in prostate cancer management in India, offering patients and doctors a new, safe, cost-effective, and convenient treatment option.

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to accelerate the development of next-generation radioconjugates to transform cancer treatment by delivering more targeted therapies that could replace traditional chemotherapy and radiotherapy regimens. Fusion Pharmaceuticals is a Canada-based clinical-stage oncology company specializing in therapies for metastatic castration-resistant prostate cancer (mCRPC).

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of advanced oncology APIs and biologics used in prostate cancer treatments, particularly impacting Europe and North America where reliance on global oncology supply chains is high. Import restrictions have contributed to pricing pressure and, in some cases, delayed access to novel therapies in hospital and specialty care settings. Rising tariff related expenses have influenced procurement planning, reimbursement discussions, and market access strategies for prostate cancer drugs. This has affected treatment availability and launch timelines for innovative oncology products. Conversely, tariffs have promoted regional manufacturing of oncology drugs, encouraged localized clinical trial activity, and strengthened long term supply resilience.

The prostate cancer therapeutics market research report is one of a series of new reports that provides prostate cancer therapeutics market statistics, including prostate cancer therapeutics industry global market size, regional shares, competitors with a prostate cancer therapeutics market share, detailed prostate cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. This prostate cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate cancer therapeutics encompass the medical treatments and interventions used to manage, control, or eliminate prostate cancer, a malignancy that develops in the prostate gland of men. These therapies aim to slow disease progression, alleviate symptoms, enhance quality of life, and, in some cases, achieve remission.

The main types of therapies in prostate cancer treatment include hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a treatment that modifies hormone levels in the body to manage or treat conditions such as cancer or hormonal disorders. It involves various drug classes, including androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and others, administered orally or via injection. These therapies are distributed through hospital pharmacies, retail pharmacies, and online platforms, serving end users such as clinics, hospitals, and others.

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.